NL2018190B1 - Psilocybin or psilocin in combination with cannabinoid - Google Patents
Psilocybin or psilocin in combination with cannabinoid Download PDFInfo
- Publication number
- NL2018190B1 NL2018190B1 NL2018190A NL2018190A NL2018190B1 NL 2018190 B1 NL2018190 B1 NL 2018190B1 NL 2018190 A NL2018190 A NL 2018190A NL 2018190 A NL2018190 A NL 2018190A NL 2018190 B1 NL2018190 B1 NL 2018190B1
- Authority
- NL
- Netherlands
- Prior art keywords
- cannabinoid
- psilocybin
- psilocin
- treatment
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2018190A NL2018190B1 (en) | 2017-01-18 | 2017-01-18 | Psilocybin or psilocin in combination with cannabinoid |
| DK18710925.1T DK3570830T3 (da) | 2017-01-18 | 2018-01-18 | Psilocybin og/eller psilocin i kombination med cannabinoider og/eller terpener |
| US16/478,283 US10729706B2 (en) | 2017-01-18 | 2018-01-18 | Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes |
| EP18710925.1A EP3570830B1 (fr) | 2017-01-18 | 2018-01-18 | Psilocybine et/ou psilocine en combinaison avec des cannabinoïdes et/ou des terpènes |
| CA3050679A CA3050679C (fr) | 2017-01-18 | 2018-01-18 | Psilocybine et/ou psilocine en combinaison avec des cannabinoides et/ou des terpenes |
| ES18710925T ES2884949T3 (es) | 2017-01-18 | 2018-01-18 | Psilocibina y/o psilocina en combinación con cannabinoides y/o terpenos |
| PCT/NL2018/050037 WO2018135943A1 (fr) | 2017-01-18 | 2018-01-18 | Psilocybine et/ou psilocine en combinaison avec des cannabinoïdes et/ou des terpènes |
| HRP20211105TT HRP20211105T1 (hr) | 2017-01-18 | 2018-01-18 | Psilocibin i/ili psilocin u kombinaciji s kanabinoidima i/ili terpenima |
| SI201830320T SI3570830T1 (sl) | 2017-01-18 | 2018-01-18 | Psilocibin in/ali psilocin v kombinaciji s kanabinoidi in/ali terpeni |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2018190A NL2018190B1 (en) | 2017-01-18 | 2017-01-18 | Psilocybin or psilocin in combination with cannabinoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2018190B1 true NL2018190B1 (en) | 2018-07-26 |
Family
ID=61627147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2018190A NL2018190B1 (en) | 2017-01-18 | 2017-01-18 | Psilocybin or psilocin in combination with cannabinoid |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10729706B2 (fr) |
| EP (1) | EP3570830B1 (fr) |
| CA (1) | CA3050679C (fr) |
| DK (1) | DK3570830T3 (fr) |
| ES (1) | ES2884949T3 (fr) |
| HR (1) | HRP20211105T1 (fr) |
| NL (1) | NL2018190B1 (fr) |
| SI (1) | SI3570830T1 (fr) |
| WO (1) | WO2018135943A1 (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016489A2 (pt) * | 2017-02-09 | 2020-04-07 | Caamtech Llc | composições e métodos compreendendo um derivado da psilocibina |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3713568A1 (fr) | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019099745A1 (fr) * | 2017-11-16 | 2019-05-23 | CaaMTech, LLC | Compositions comprenant un dérivé de psilocybine et un cannabinoïde |
| WO2019246532A1 (fr) * | 2018-06-21 | 2019-12-26 | Robert John Petcavich | Procédé d'induction de la genèse dendritique et synaptique dans des maladies neurodégénératives chroniques |
| WO2020181194A1 (fr) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions et méthodes d'utilisation comprenant des substances ayant des actions de plasticité neurale administrées à des doses et formulations non psychédéliques/psychotomimétiques |
| CN113993522A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法 |
| DE102019117739A1 (de) | 2019-07-01 | 2021-01-07 | Felix Blei | Arylalkyamin-, Pyrrol-, Indol- und Opiatderivatkonzentrationsbestimmungsverfahren sowie Testkit unter Verwendung dieses Verfahrens |
| WO2021003467A1 (fr) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Compositions de dosage et procédés d'utilisation de composés psychédéliques |
| WO2021016710A1 (fr) * | 2019-07-30 | 2021-02-04 | Tassili Life Sciences, Corp. | Formulations à libération contrôlée de multiples agents pharmaceutiques actifs, et agents dérivés de psilocybe combinés avec des agents dérivés du cannabis et leurs procédés d'utilisation |
| CA3147679A1 (fr) * | 2019-08-13 | 2021-02-18 | Scott Thompson | Methodes de traitement de troubles psychologiques et cerebraux |
| AU2020358720A1 (en) | 2019-10-01 | 2022-04-21 | Empyrean Neuroscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CA3156257A1 (fr) | 2019-10-03 | 2021-04-08 | Starton Therapeutics, Inc. | Administration transdermique de dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| AU2020361741B2 (en) | 2019-10-11 | 2024-09-05 | Pike Therapeutics Inc. | Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| CN114555068A (zh) | 2019-10-14 | 2022-05-27 | 长矛治疗股份有限公司1219014 B.C.有限公司 | 大麻二酚的透皮给药 |
| WO2021072530A1 (fr) * | 2019-10-15 | 2021-04-22 | Tassili Life Sciences, Corp. | Formulations à libération contrôlée d'agents dérivés de psilocybes et leur procédé d'utilisation, et procédés et compositions pour traiter une lésion cérébrale traumatique légère avec un syndrome de stress post-traumatique |
| IL292404A (en) * | 2019-10-21 | 2022-06-01 | Esolate Ltd | Compositions including thin compounds and their production |
| AU2020386445A1 (en) | 2019-11-19 | 2022-06-02 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| BR112022017097A2 (pt) * | 2020-02-28 | 2022-11-16 | Univ Basel | Composição e uso da composição |
| US11801278B2 (en) * | 2020-03-05 | 2023-10-31 | Cure Pharmaceutical, Inc. | Method for obtaining an extract of a plant biomass |
| CA3169783A1 (fr) | 2020-03-19 | 2021-09-23 | Andrew R. Chadeayne | Derives cristallins de psilacetine |
| US20240277736A1 (en) * | 2020-04-17 | 2024-08-22 | Revive Therapeutics Ltd | Use of psilocybin in the treatment of neurological brain injury and migraines |
| US20210346338A1 (en) * | 2020-05-07 | 2021-11-11 | Trinidad Consulting, Llc | Cannabinoid pouches |
| PH12022553135A1 (en) | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2021234608A1 (fr) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Dérivés de tryptamine deutérés et procédés d'utilisation |
| MX2022016533A (es) | 2020-06-17 | 2023-04-05 | Psilo Scientific Ltd | Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. |
| US12233355B2 (en) | 2020-06-17 | 2025-02-25 | Psilo Scientific Ltd. | Methanol-based extraction of psychoactive alkaloids from fungus |
| US20230277568A1 (en) * | 2020-07-10 | 2023-09-07 | Eleusis Therapeutics Us, Inc. | Method of treatment for psilocybin or psilocin infusion |
| WO2022018709A1 (fr) * | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions et méthodes de traitement de psychoses et de troubles psychotiques |
| US20230405028A1 (en) * | 2020-10-12 | 2023-12-21 | Goodcap Pharmaceuticals Ltd. | Compositions for reducing inflammation to improve or maintain mental or physical health |
| WO2022082058A1 (fr) * | 2020-10-16 | 2022-04-21 | Eleusis Therapeutics Us, Inc. | Méthode de traitement par alcaloïdes tryptamines |
| WO2022094719A1 (fr) * | 2020-11-06 | 2022-05-12 | Pacific Myco Biosciences Ltd. | Procédé de traitement de la dépression par modulation immunitaire |
| CA3113240C (fr) | 2020-12-28 | 2023-09-05 | Psilo Scientific Ltd. | Composition d'alcaloide psychoactif transmucosal et preparation connexe |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| AU2022218986A1 (en) * | 2021-02-10 | 2023-09-21 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| WO2022187973A1 (fr) * | 2021-03-12 | 2022-09-15 | Allied Corp. | Schémas posologiques de compositions pharmaceutiques et nutraceutiques de champignon et de cannabis et leur utilisation pour traiter des troubles du système nerveux central et améliorer la santé mentale |
| TW202304423A (zh) * | 2021-04-01 | 2023-02-01 | 美商泰仁生物科學公司 | 與致幻劑及血清素受體調節劑相關之方法及組合物 |
| WO2022235531A1 (fr) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Troubles du mouvement |
| US20240261419A1 (en) * | 2021-05-10 | 2024-08-08 | London Pharmaceuticals And Research Corporation | Psilocybin and psilocin conjugates for treatment of mental illnesses |
| CA3219041A1 (fr) | 2021-05-24 | 2022-12-01 | Canna-Chemistries Llc | Sels cristallins de psilocine |
| CN117642383A (zh) * | 2021-05-24 | 2024-03-01 | 卡纳-化学有限责任公司 | 二甲-4-羟色胺的结晶盐 |
| CA3224112A1 (fr) * | 2021-06-24 | 2022-12-29 | David Feifel | Traitement medicamenteux psychedelique de troubles neuropsychiatriques et de paralysie cerebrale |
| US20240366638A1 (en) * | 2021-06-25 | 2024-11-07 | Synaptive Therapeutics Llc | Psilocybin analogs for treating psychological disorders |
| TW202317545A (zh) | 2021-07-07 | 2023-05-01 | 美商泰仁生物科學公司 | N,n-二甲基色胺及相關致幻劑及其用途 |
| CA3237988A1 (fr) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybine et o-acetylpsilocine, leurs sels et formes a l'etat solide |
| WO2023130078A2 (fr) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Mycélium génétiquement modifié pour la production d'alcaloïdes psychotropes |
| EP4486448A1 (fr) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-cristaux ou sels comprenant de la psilocine |
| WO2023215342A1 (fr) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions et procédés de traitement de la névralgie du trijumeau |
| WO2023215344A2 (fr) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions et procédés de traitement du syndrome cluster-tic |
| WO2023215338A1 (fr) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions et procédés de traitement de l'algie vasculaire de la face |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
| WO2024098160A1 (fr) * | 2022-11-10 | 2024-05-16 | Allen Greenspoon | Formulation administrable par voie orale |
| AU2024220413A1 (en) * | 2023-02-17 | 2025-09-25 | Native Code Bio, Llc | Therapeutic combinations for inflammatory conditions and disorders |
| WO2024238035A1 (fr) * | 2023-05-16 | 2024-11-21 | Mind Medicine, Inc. | Troubles du mouvement |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2383700A (en) | 2001-09-27 | 2003-07-02 | Inquam | Frequency converter for CDMA systems |
| GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
| GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| WO2009043395A2 (fr) | 2007-10-05 | 2009-04-09 | Sti Pharmaceuticals Ltd. | Composition pharmaceutique |
| CA2968703A1 (fr) | 2015-05-19 | 2016-11-24 | Joseph Robert Knight | Procede d'isolation d'alcaloides et d'acides amines, et compositions contenant des alcaloides et des acides amines isoles |
-
2017
- 2017-01-18 NL NL2018190A patent/NL2018190B1/en active
-
2018
- 2018-01-18 ES ES18710925T patent/ES2884949T3/es active Active
- 2018-01-18 HR HRP20211105TT patent/HRP20211105T1/hr unknown
- 2018-01-18 DK DK18710925.1T patent/DK3570830T3/da active
- 2018-01-18 CA CA3050679A patent/CA3050679C/fr active Active
- 2018-01-18 WO PCT/NL2018/050037 patent/WO2018135943A1/fr not_active Ceased
- 2018-01-18 US US16/478,283 patent/US10729706B2/en active Active
- 2018-01-18 EP EP18710925.1A patent/EP3570830B1/fr active Active
- 2018-01-18 SI SI201830320T patent/SI3570830T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3050679C (fr) | 2024-04-23 |
| CA3050679A1 (fr) | 2018-07-26 |
| SI3570830T1 (sl) | 2021-11-30 |
| HRP20211105T1 (hr) | 2021-10-15 |
| EP3570830A1 (fr) | 2019-11-27 |
| DK3570830T3 (da) | 2021-07-12 |
| EP3570830B1 (fr) | 2021-04-21 |
| WO2018135943A1 (fr) | 2018-07-26 |
| US10729706B2 (en) | 2020-08-04 |
| US20190350949A1 (en) | 2019-11-21 |
| ES2884949T3 (es) | 2021-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL2018190B1 (en) | Psilocybin or psilocin in combination with cannabinoid | |
| US20220226257A1 (en) | Use of cannabinoids in the treatment of comorbidities associated with epilepsy | |
| US9017737B2 (en) | Use of cannabinoids in combination with an anti-psychotic medicament | |
| US10653641B2 (en) | Use of cannabinoids in the treatment of mental disorders | |
| KR20220147636A (ko) | 칸나비디올 및 에버롤리무스에 의한 복합 결절성 경화증 치료 방법 | |
| KR20200094756A (ko) | 간질의 치료에서 칸나비노이드의 용도 | |
| RS60767B1 (sr) | Upotreba kanabinoida u lečenju atoničnih napada kod lenoks-gastoovog sindroma | |
| Chkonia et al. | Patients with functional psychoses show similar visual backward masking deficits | |
| Reznik et al. | Cannabidiol: a potential treatment for post Ebola syndrome? | |
| HK40017964A (en) | Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes | |
| HK40017964B (en) | Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes | |
| US20230000793A1 (en) | Treatment of 22q11.2 deletion syndrome with cannabidiol | |
| US11253519B2 (en) | Composition used to improve symptoms of autism spectrum disorder, and method using same for improving symptoms of autism spectrum disorder | |
| Kocak et al. | Autophagy–NAD+ axis: Emerging insights into neuronal homeostasis and neurodegenerative diseases | |
| CN120417909A (zh) | 格列齐特的新用途 | |
| RU2660583C1 (ru) | Применение буспирона для лечения функционального головокружения | |
| Vgenopoulou et al. | Melatonin levels in Alzheimer disease | |
| Ahmed et al. | Severe depression and behavioral disturbance, an unusual presentation of intracerebral hemorrhage in a 78-year-old man | |
| HK1186416A (en) | Use of cannabinoids in combination with aripiprazole |